Pearson's General Thoracic
Lung Volume Reduction Surgery
To view the entire topic, please log in or purchase a subscription.
STS Cardiothoracic Surgery E-Book from The Society of Thoracic Surgeons provides expert guidance for Cardiac and Thoracic Surgery. Sections include Pearson’s General Thoracic, Esphageal, Adult Cardiac, and Pediatric and Congenital Cardiac Surgery. Explore these free sample topics:
-- The first section of this topic is shown below --
Key Points
- Lung volume reduction surgery is a viable option for a select group of patients with emphysema.
- Preoperative pulmonary rehabilitation and meticulous patient selection are essential ingredients for favorable outcomes.
- In appropriately selected patients, LVRS can improve dyspnea, improve exercise tolerance, and may improve survival. Individuals with predominantly upper-lobe emphysema and low baseline exercise capacity represent a subgroup of patients who seem most likely to experience a survival benefit from LVRS.
Over 12 million Americans have chronic obstructive pulmonary disease (COPD). As many as 2 million of these patients have the specific diagnosis of emphysema.[1] Emphysema is a progressive disease that results in a continued decline in pulmonary function. When pulmonary function tests document a forced expiratory volume in 1 second (FEV1) of less than 30% of the value predicted by nomograms, the 3-year mortality risk has been estimated at 40% to 50%. Medical therapy is the mainstay of treatment for most patients.[2] Although lung transplantation is a viable option, the scarcity of available donors and the presence of associated comorbidities in patients with advanced emphysema limit the transplant option to a select few. An additional surgical therapy—lung volume reduction surgery (LVRS)—has been a viable treatment modality more than 2 decades. In this chapter, we review the physiologic basis of LVRS, the proper selection of patients, and the best data on long term outcomes for the procedure.
-- To view the remaining sections of this topic, please log in or purchase a subscription --
Key Points
- Lung volume reduction surgery is a viable option for a select group of patients with emphysema.
- Preoperative pulmonary rehabilitation and meticulous patient selection are essential ingredients for favorable outcomes.
- In appropriately selected patients, LVRS can improve dyspnea, improve exercise tolerance, and may improve survival. Individuals with predominantly upper-lobe emphysema and low baseline exercise capacity represent a subgroup of patients who seem most likely to experience a survival benefit from LVRS.
Over 12 million Americans have chronic obstructive pulmonary disease (COPD). As many as 2 million of these patients have the specific diagnosis of emphysema.[1] Emphysema is a progressive disease that results in a continued decline in pulmonary function. When pulmonary function tests document a forced expiratory volume in 1 second (FEV1) of less than 30% of the value predicted by nomograms, the 3-year mortality risk has been estimated at 40% to 50%. Medical therapy is the mainstay of treatment for most patients.[2] Although lung transplantation is a viable option, the scarcity of available donors and the presence of associated comorbidities in patients with advanced emphysema limit the transplant option to a select few. An additional surgical therapy—lung volume reduction surgery (LVRS)—has been a viable treatment modality more than 2 decades. In this chapter, we review the physiologic basis of LVRS, the proper selection of patients, and the best data on long term outcomes for the procedure.
There's more to see -- the rest of this topic is available only to subscribers.
